Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23277737 | 0.84 | — | — | |
| SCHEMBL20224784 | 0.83 | NAMPT (0.30) | NAMPT | |
| SCHEMBL9944699 | 0.75 | NAMPT (0.35) | NAMPTCDK1MYT1SPR | |
| SCHEMBL18702115 | 0.71 | NAMPT (0.44) | NAMPTCDK1MYT1SPR | |
| SCHEMBL10361609 | 0.70 | NAMPT (0.33) | NAMPTCDK1MYT1SPR | |
| SCHEMBL4401620 | 0.68 | KCNQ2 (0.39) | — | |
| SCHEMBL13151205 | 0.67 | FGFR1 (0.31) | — | |
| SCHEMBL15448154 | 0.67 | DRD2 (0.36) | CDK1MYT1 | |
| SCHEMBL17326270 | 0.67 | NAMPT (0.31) | NAMPT | |
| SCHEMBL20249400 | 0.66 | SOS1 (0.33) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| US-20120129843-A1 | PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129843-A1 | PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | NAMPT 968/4885CDK1 4645/4885MYT1 2226/4885 |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MAPK1, MAPK6, MAPK3 | NAMPT 417/4885CDK1 102/4885MYT1 3091/4885 |
| US-20120129843-A1 | PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP9, TIMP3 | NAMPT 601/4885CDK1 522/4885MYT1 645/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | NAMPT 76/4885CDK1 1087/4885MYT1 4532/4885 |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | NAMPT 748/4885CDK1 186/4885MYT1 2137/4885 |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | TRPV1, CACNA1B, CACNA1G | NAMPT 2189/4885CDK1 2989/4885MYT1 1634/4885 |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | NAMPT 2450/4885CDK1 2393/4885MYT1 629/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | NAMPT 847/4885CDK1 40/4885MYT1 3229/4885 |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | ROS1, ALK, ROR1 | NAMPT 1109/4885CDK1 95/4885MYT1 1160/4885 |
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | NAMPT 3694/4885CDK1 386/4885MYT1 3293/4885 |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | NAMPT 1243/4885CDK1 332/4885MYT1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.